Nizatidine: Indications, Dosing, and Precautions
Primary Indications
Nizatidine is an H2-receptor antagonist indicated for treating erosive esophagitis and GERD in children ≥12 years at 10 mg/kg/day divided twice daily, and in adults for duodenal ulcer, GERD with esophagitis, and benign gastric ulcer. 1, 2
FDA-Approved Adult Indications 2:
- Active duodenal ulcer: up to 8 weeks (most heal within 4 weeks)
- Duodenal ulcer maintenance: 150 mg at bedtime after healing
- GERD with erosive/ulcerative esophagitis: up to 12 weeks
- Active benign gastric ulcer: up to 8 weeks (exclude malignancy first)
Pediatric Use 1:
- FDA-approved for ages ≥12 years only
- Randomized controlled trials demonstrate superiority over placebo for erosive esophagitis in children 1
- Available as bubble gum-flavored solution for pediatric administration
Dosing Recommendations
Pediatric Dosing (GERD/Esophagitis) 1:
- 10 mg/kg/day divided in 2 doses (5 mg/kg per dose BID)
- Onset: gastric pH increases within 30 minutes
- Peak effect: 2.5 hours post-dose
- Duration: approximately 6 hours of acid suppression
Adult Dosing 2:
- Active duodenal ulcer: 300 mg once daily at bedtime OR 150 mg BID
- Maintenance therapy: 150 mg at bedtime
- GERD: 150 mg BID (more effective than 300 mg at bedtime) 3
Renal Impairment Dosing 2, 4:
Critical adjustment required as nizatidine is primarily renally excreted:
- CrCl <50 mL/min: 150 mg once daily at bedtime
- CrCl <20 mL/min: 150 mg every other night
- Elimination half-life increases from 1.5 hours (normal) to 6.9 hours (renal failure) 4
- Not substantially removed by hemodialysis 4
Important Precautions and Limitations
Key Safety Concerns 1, 2:
Tachyphylaxis: Rapid tolerance develops within 6 weeks, limiting long-term effectiveness 1
Inferior to PPIs: H2RAs are less effective than proton pump inhibitors for symptom relief and healing erosive esophagitis 1
Renal monitoring: Essential in elderly patients who are more likely to have decreased renal function 2
Exclude malignancy: Symptomatic response does not rule out gastric cancer—always exclude malignancy before treating gastric ulcers 2
Class-Related Concerns 1:
While cimetidine specifically causes liver disease and gynecomastia, these associations may potentially generalize to other H2RAs including nizatidine 1
Formulation Considerations 5:
- Capsule and commercial oral syrup: bioequivalent
- Apple juice extemporaneous solution: significantly reduced bioavailability (30-50% lower)—avoid this formulation 5
- Infant formula suspension: bioequivalent to capsule 5
Pregnancy and Lactation 2:
- Pregnancy Category B: no evidence of fetal harm in animal studies, but use only if clearly needed
- Nursing: 0.1% of dose secreted in breast milk; consider discontinuing nursing or drug based on maternal need
Drug Interactions 2:
- No significant interactions with theophylline, benzodiazepines, lidocaine, phenytoin, or warfarin
- High-dose aspirin (3,900 mg/day): may increase salicylate levels
- Does not inhibit cytochrome P-450 system
Rare but Serious Adverse Effects 6:
Extrapyramidal symptoms (parkinsonism, akathisia) reported when combined with antipsychotics—monitor closely if co-prescribed
Clinical Effectiveness
In pediatric studies, approximately 30% of patients became asymptomatic after 8 weeks regardless of dose or formulation, with reduction in antacid use in 50% of patients 7. The drug is generally well-tolerated with mostly mild-to-moderate adverse events related to concurrent infectious illnesses rather than the medication itself 7.
For adults with GERD, nizatidine 150 mg BID is significantly more effective than 300 mg at bedtime for healing erosive and ulcerative esophagitis (29% vs 13% healing at 12 weeks) 3.